Abstract:Although chronic activation is considered a major driver of T cell dysfunction in the tumor microenvironment (TME), there is a virtual absence of methodologies to discern how T cells spatiotemporally progress through activation states into that dysfunction. Furthermore, T cells and other immune populations in the TME communicate extensively with tumor-associated macrophages (TAMs) which are typically simply described as 'suppressive', but whose functions are certainly more complex. To address these critical knowledge gaps, we designed two types of novel genetic marking systems to visualize, track and manipulate (i) T cell subsets with distinct activation histories and (ii) specific subsets of macrophages, modulating primarily those in the TME, to study and define these co-evolving immune states. We generated a novel T cell activation reporter mouse, which is a transcriptional reporter of CD69 expressing the fluorescent protein TFP. By recording transcriptional activity of a locus where the protein expression is under tight, activation-dependent post-transcriptional control, we generated a reporting system to read out contemporary as well as historic T cell triggering. While cell surface CD69 reliably indicates current activation, resting TFP (Cd69 mRNA) expression is downregulated with successive TCR triggering and hence an inverse marker of chronic stimulation. Using multiple tumor models in vivo, tumor slice cultures ex vivo and scRNA-Seq, we thus defined and tracked over time distinct functional states of intratumoral T cells based on their activation histories. These data revealed key insights including the delineation of quiescent versus activated states within progenitor, effector and exhausted T cells and the trajectory of inter-conversion that leads to the emergence of these states in the TME. Probing the inflection points in this differentiation trajectory reveals a particularly interesting subset of CD69+TFP+ cells, representing intratumorally activated effector CD8 T cells prior to their dysfunctional adaptation to chronic stimulation. Dissecting their phenotype led to the discovery of a previously unexplored subset of intratumoral T cells of functional significance. Indeed, these cells were enriched specifically in the context of T cell-mediated tumor control in mice and their phenotypic markers correlated with improved outcomes and survival in human patients. To complement this system, we generated a second genetic strain of mice that allowed specific depletion of TAMs. The prevailing view of M1 vs. M2 TAMs as ostensibly anti-tumor vs. pro-tumor, although useful, is almost certainly over-simplistic and has lacked further delineation, limited by the quality of available tools to specifically manipulate TAMs in situ. Remarkably, till now, a method to specifically deplete TAMs, without global depletion of all macrophages (e.g CSF1R blockade, Clodronate) did not exist. We alleviated this problem by using this novel mouse strain, in which conditional (lox-Stop-lox flanked) YFP and DTR genes are knocked into the endogenous CD206 locus. Since, within macrophages, CD206 is largely expressed in tumors, an intercross of this allele with a Csf1r-Cre (to specify monocyte-derived lineage) provides a 2-allele gating system to limit and robustly penetrate reporter and depletion function to TAMs. In multiple TAM-rich tumor models, this revealed that TAMs assumed context-dependent divergent roles in anti-tumor immunity. On the one hand, their removal led to a mitigation of T cell exhaustion, consistent with the popular notion that they are immunosuppressive and in need of global elimination. However, our data also reveals that macrophage depletion not only fails to alleviate the tumor burden but also prevents successful T cell-mediated anti-tumor immunity. We linked the latter effect to an obligate role for TAMs in the recruitment and maintenance of cDC1s and CD8 T cells in the TME, respectively. By live imaging of TAMs in vivo using the reporter and subsequent spatially resolved scRNA-Seq, the key TAM subsets and interactional networks involved in these processes were established. Importantly, in responsive tumor models, TAM depletion subverted T cell-mediated tumor control, demonstrating their importance in organizing anti-tumor adaptive immunity. We thus combine the use of novel engineered mice in vivo, real time imaging and spatial transcriptomics with functional studies to shed new light on immune dysfunction in the TME. Defining the ontology of functional immune states in the TME provides a clear target space to maneuver cancer immunotherapies. Herein, we offer prime examples of dissecting the spatiotemporal biology of CD8 T cells and TAMs in anti-tumor immunity to define such interdependent states. These findings and the newly established models therein pave the way to deepen as well as broaden our understanding of the complex immu -Abstract Truncated-

Abstract B031: TCR signal strength drives tumor-specific CD8 T cell differentiation

Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms

Abstract PR-03: Competition for dendritic cells limits engineered TCR-T cell activation in tumor-draining lymph nodes and impairs synergy with PD-L1 blockade

Abstract A033: Pro-inflammatory tumor cells drive CD4+ T cell localization within heterogeneous tumors

Abstract 3961: Impact of CD8 resident memory T cells on antitumor immunity and response to cancer immunotherapy

Abstract 3606: Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors

Abstract 7042: Enhancing TCR T cell function in solid tumors through in vivo combinatorial screens and single-cell analysis

Abstract PR02: Tumor sequestered, neoantigen specific T cells are dynamically increased in circulation following neoadjuvant immunotherapy

Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts

Abstract B045: Tumor- and T-cell-centric parameters shape the immunogenicity of cancer neoantigens and determine productive antitumor CD8+ T cell responses

Abstract SY19-04: Next-generation macrophage and T cell activation reporters to define functional immune states in solid tumors

Abstract 1780: TCR-T and CAR-T cells targeting HLA-A2/MAGEA4 demonstrate differential tumor control, reflecting co-stimulatory signaling requirements

Tumor-Reactive CD8+ T Cells Enter a TCF1+PD-1- Dysfunctional State

Abstract 5083: Investigating the development and therapeutic potential of intra-tumoral CXCR6+ effector/effector memory T cells (TEFF/EM) in triple-negative breast cancer

Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion.

TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity

Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells

Abstract LB073: Adoptive transfer of one CD4TCR and one CD8TCR targeting autochthonous neoantigens are essential and sufficient for eradication of naturally heterogeneous solid tumors

Abstract B041: Defining the Determinants of Immune Response in DNA Homologous Recombination Deficient Tumors

Abstract 14: Identification of tumor-reactive T cell receptors through functional single cell interaction analyses for personalized T cell therapy

Abstract 4991: Radiotherapy-induced immunological and therapeutic response depends on stem-like TCF-1+PD-1+CD8+ T-cells